Muharrem Muftuoglu, Enping Hong, Nosha Farhadfar, Stephen Strickland, Ashish Bajel, Alireza Eghtedar, Gary Schiller, Mahesh Basyal, Li Li, Lawrence Naitmazi, Rochelle Emery, Timothy Lu, Brian Garrison, Kanya Rajangam, Farhad Ravandi, Michael Andreeff. "Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML) is consistent with its clinical activity and unique logic gated mechanism of action." Blood (2025). https://doi.org/10.1182/blood-2025-5921